Olanzapine long acting injectable (Teva Pharmaceutical Industries)

奥氮平长效注射剂 (以色列梯瓦制药工业有限公司)

Report date: 2026/05/22 14:57:09

Base Information

Drug NameOlanzapine long acting injectable (Teva Pharmaceutical Industries)
Drug Alias NameTV-44749TEV-‘749mdc-TJKTEV-749
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D1 receptor antagonistsDopamine D2 receptor antagonistsSerotonin 2 (5-HT2) receptor antagonists
TargetsDopamine D1 receptorDopamine D2 receptorSerotonin 2 (5-HT2) receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesRomania +[9] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMedincell SA
China Registration ClassN/A

Develop Information

Active CompaniesTeva Branded Pharmaceutical Products R&D LLCTeva Pharmaceuticals SrlTeva Pharmaceutical Industries Ltd
Inactive CompaniesPliva Croatia LtdTeva Branded Pharmaceutical Products R&D IncTeva Pharmaceutical Investments (Shanghai) Ltd
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A